SAN DIEGO, CA, June 15 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN - News) today announced results, recently published in the journal AIDS, from a clinical trial to test HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on patients with high-grade anal intraepithelial neoplasia (AIN), or dysplasia, in HIV-positive individuals. The trial was conducted by the AIDS Malignancy Consortium at the University of California in San Francisco and was sponsored by the U.S. National Cancer Institute
